Literature DB >> 30143566

Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA).

Phillip Mongiovi1, Nuran Dilek2, Connie Garland2, Michael Hunter2, John T Kissel2, Elizabeth Luebbe2, Michael P McDermott2, Nicholas Johnson2, Chad Heatwole2.   

Abstract

OBJECTIVE: To determine the frequency and relative importance of symptoms experienced by adults with spinal muscular atrophy (SMA) and to identify factors that are associated with a higher burden of disease in this population.
METHODS: We conducted a cross-sectional study of 359 adults with SMA using the International SMA Patient Registry. Participants provided input regarding 20 symptomatic themes and 207 symptoms that potentially affect adults with SMA. Participants were asked about the relative importance of each symptom, and analysis was conducted to determine how age, sex, SMA type, education, mobility, and employment status relate to symptom prevalence.
RESULTS: Limitations with mobility or walking (98.6%) and the inability to do activities (98.6%) were the 2 themes with the highest prevalence in the study sample. Limitation with mobility or walking was the theme that was identified as having the greatest effect on the lives of adults with SMA. Employment status was associated with the prevalence of 4 of 20 themes and a reliance on an assistive device was associated with 7 of 20 themes. The prevalence of breathing difficulties, choking or swallowing difficulties, and communication difficulties differed among those with different SMA types.
CONCLUSIONS: There are many symptomatic themes that affect the lives of adults with SMA. These themes vary in prevalence and relative importance in the adult SMA population.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 30143566      PMCID: PMC6161547          DOI: 10.1212/WNL.0000000000006241

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


  11 in total

1.  International SMA consortium meeting. (26-28 June 1992, Bonn, Germany).

Authors:  T L Munsat; K E Davies
Journal:  Neuromuscul Disord       Date:  1992       Impact factor: 4.296

2.  The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Generic Core Scales and Neuromuscular Module.

Authors:  Susan T Iannaccone; Linda S Hynan; Anne Morton; Renee Buchanan; Christine A Limbers; James W Varni
Journal:  Neuromuscul Disord       Date:  2009-10-28       Impact factor: 4.296

3.  What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients.

Authors:  Michael Hunter; Chad Heatwole; Elizabeth Luebbe; Nicholas E Johnson
Journal:  J Neuromuscul Dis       Date:  2016-08-30

4.  Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Authors:  Chad Heatwole; Rita Bode; Nicholas Johnson; Christine Quinn; William Martens; Michael P McDermott; Nan Rothrock; Charles Thornton; Barbara Vickrey; David Victorson; Richard Moxley
Journal:  Neurology       Date:  2012-07-11       Impact factor: 9.910

5.  Quality-of-life in Charcot-Marie-Tooth disease: the patient's perspective.

Authors:  Nicholas E Johnson; Chad R Heatwole; Nuran Dilek; Janet Sowden; Callyn A Kirk; Denise Shereff; Michael E Shy; David N Herrmann
Journal:  Neuromuscul Disord       Date:  2014-06-27       Impact factor: 4.296

6.  A natural history study of late onset spinal muscular atrophy types 3b and 4.

Authors:  S Piepers; L H van den Berg; F Brugman; H Scheffer; M Ruiterkamp-Versteeg; B G van Engelen; C G Faber; M de Visser; W-L van der Pol; J H J Wokke
Journal:  J Neurol       Date:  2008-06-30       Impact factor: 4.849

7.  Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications.

Authors:  K Zerres; S Rudnik-Schöneborn
Journal:  Arch Neurol       Date:  1995-05

8.  Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).

Authors:  Chad Heatwole; Nicholas Johnson; Rita Bode; Jeanne Dekdebrun; Nuran Dilek; James E Hilbert; Elizabeth Luebbe; William Martens; Michael P McDermott; Christine Quinn; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Neurology       Date:  2015-11-18       Impact factor: 9.910

9.  Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens.

Authors:  Elaine A Sugarman; Narasimhan Nagan; Hui Zhu; Viatcheslav R Akmaev; Zhaoqing Zhou; Elizabeth M Rohlfs; Kerry Flynn; Brant C Hendrickson; Thomas Scholl; Deborah Alexa Sirko-Osadsa; Bernice A Allitto
Journal:  Eur J Hum Genet       Date:  2011-08-03       Impact factor: 4.246

10.  Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study.

Authors:  Ying Qian; Sarah McGraw; Jeff Henne; Jill Jarecki; Kenneth Hobby; Wei-Shi Yeh
Journal:  BMC Neurol       Date:  2015-10-24       Impact factor: 2.474

View more
  14 in total

Review 1.  Spinal muscular atrophy: state of the art and new therapeutic strategies.

Authors:  Sonia Messina; Maria Sframeli; Lorenzo Maggi; Adele D'Amico; Claudio Bruno; Giacomo Comi; Eugenio Mercuri
Journal:  Neurol Sci       Date:  2021-04-19       Impact factor: 3.307

Review 2.  Spinal muscular atrophy - insights and challenges in the treatment era.

Authors:  Eugenio Mercuri; Maria Carmela Pera; Mariacristina Scoto; Richard Finkel; Francesco Muntoni
Journal:  Nat Rev Neurol       Date:  2020-10-14       Impact factor: 42.937

3.  Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.

Authors:  Silvia Bonanno; Riccardo Zanin; Luca Bello; Irene Tramacere; Virginia Bozzoni; Luca Caumo; Manfredi Ferraro; Sara Bortolani; Gianni Sorarù; Mauro Silvestrini; Veria Vacchiano; Mara Turri; Raffaella Tanel; Rocco Liguori; Michela Coccia; Renato Emilio Mantegazza; Tiziana Mongini; Elena Pegoraro; Lorenzo Maggi
Journal:  J Neurol       Date:  2022-01-03       Impact factor: 4.849

Review 4.  Congenital or Early Developing Neuromuscular Diseases Affecting Feeding, Swallowing and Speech - A Review of the Literature from January 1998 to August 2021.

Authors:  Lotta Sjögreen; Lisa Bengtsson
Journal:  J Neuromuscul Dis       Date:  2022

5.  "I have SMA, SMA doesn't have me": a qualitative snapshot into the challenges, successes, and quality of life of adolescents and young adults with SMA.

Authors:  Allison Mazzella; Mary Curry; Lisa Belter; Rosángel Cruz; Jill Jarecki
Journal:  Orphanet J Rare Dis       Date:  2021-02-22       Impact factor: 4.123

6.  Patient-Reported Symptoms in Facioscapulohumeral Muscular Dystrophy (PRISM-FSHD).

Authors:  Johanna Hamel; Nicholas Johnson; Rabi Tawil; William B Martens; Nuran Dilek; Michael P McDermott; Chad Heatwole
Journal:  Neurology       Date:  2019-08-13       Impact factor: 9.910

7.  "Getting ready for the adult world": how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being.

Authors:  Hamish W Y Wan; Kate A Carey; Arlene D'Silva; Nadine A Kasparian; Michelle A Farrar
Journal:  Orphanet J Rare Dis       Date:  2019-04-02       Impact factor: 4.123

8.  Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review.

Authors:  Hamish W Y Wan; Kate A Carey; Arlene D'Silva; Steve Vucic; Matthew C Kiernan; Nadine A Kasparian; Michelle A Farrar
Journal:  Orphanet J Rare Dis       Date:  2020-03-12       Impact factor: 4.123

Review 9.  In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy.

Authors:  Kristine S Ojala; Emily J Reedich; Christine J DiDonato; Stephen D Meriney
Journal:  Brain Sci       Date:  2021-02-05

10.  Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests.

Authors:  Bart Bartels; Janke F de Groot; Laura E Habets; Camiel A Wijngaarde; Wendy Vink; Marloes Stam; Fay-Lynn Asselman; Ruben P A van Eijk; W Ludo van der Pol
Journal:  Orphanet J Rare Dis       Date:  2020-03-23       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.